Diabetic retinopathy prevalence and risk factors at a Da Nang hospital
Official title: Diabetic Retinopathy Prevalence And Risk Factors From A Hospital - Based Cohort In Central Vietnam
Run by Da Nang Family General Hospital · NCT07468058 · Data updated 2026-11-12
We will find how common different stages of diabetic retinopathy are and which clinical or lab factors are linked to it among adults with diabetes treated at a Da Nang hospital.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Da Nang Family General Hospital Academic / other |
| Locations | 1 site (Da Nang) |
| Status | Recruiting |
| Started | November 25, 2025 |
| Main results expected | March 15, 2026 |
| Study ends | March 30, 2026 |
| Registry record updated | March 12, 2026 |
| Trial ID | NCT07468058 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with diagnosed type 1 or type 2 diabetes who underwent dilated fundus examination and OCT and have available key clinical and laboratory data in the hospital's electronic records.
✕Probably not a fit
People with gestational diabetes, media opacities that prevented fundus examination, other retinal diseases, recent intraocular surgery, or incomplete medical records are unlikely to benefit or be included in the analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a retrospective observational chart review of patients with diagnosed diabetes who received dilated fundus examinations and optical coherence tomography (OCT) at a general hospital in Da Nang, Vietnam. Investigators will extract clinical and laboratory data from electronic medical records to determine the prevalence and distribution of DR stages. They will analyze associations between DR presence/severity and factors such as diabetes duration, glycemic control, blood pressure, and other clinical tests. Results aim to inform local screening and management priorities to reduce preventable vision loss.
Why it matters
Potential benefit: If clear risk patterns are identified, the results could help target screening and treatment to reduce preventable vision loss in the local diabetes population.
How similar studies have gone: Similar hospital-based prevalence and risk-factor reviews have been done worldwide and have reliably identified common risk factors such as longer diabetes duration, poor glycemic control, and hypertension.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed diabetes mellitus (type 1 or type 2) according to ADA criteria * Underwent ophthalmic examination including dilated fundus examination and OCT * Available electronic medical records with key clinical and laboratory data Exclusion Criteria: * Gestational diabetes mellitus * Media opacity precluding fundus examination (advanced cataract, corneal opacity, dense vitreous hemorrhage) * Other retinal diseases (e.g., hypertensive retinopathy, retinal vein occlusion) * History of ocular trauma or intraocular surgery within 6 months
Where it's running
-
Department of Endocrinology and Diabetes
Da Nang, Vietnam Recruiting
Study contacts
- Principal investigator: Thao Nguyen Ngoc, Doctor of Medicine — Family Hospital, Da Nang, Vietnam
- Study coordinator: Thảo Nguyễn, MD
- Email: ngocthao090897@gmail.com
- Phone: 84335393897
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Automated AI system to detect diabetic retinopathy in adults with diabetes
A AI-based software device is being tested to automatically detect diabetic retinopathy from retinal images in adults with diabetes.
-
N-acetylcysteine for diabetic retinopathy in adults with type 2 diabetes
This study tests whether taking N-acetylcysteine for three months can help people with type 2 diabetes who have mild to moderate diabetic retinopathy.
-
Early imaging changes with faricimab versus biosimilar ranibizumab for diabetic retinal disease
This trial will see if faricimab or a biosimilar ranibizumab causes different early OCT and OCTA imaging changes in adults with diabetic retinopathy or diabetic macular edema who need anti-VEGF injections.
-
Finding protein biomarkers for AMD, diabetic retinopathy, and retinal detachment
This project will test whether proteins found in blood and eye fluids can help diagnose or predict outcomes for adults with AMD, diabetic retinopathy, or retinal detachment.
-
AI-assisted retinal photo screening for adults with diabetes
This will test whether adding the VUNO Med®-Fundus AI tool to routine retinal photo screening helps adults with type 2 diabetes get more accurate referrals for diabetic retinopathy.
-
New-generation diabetes medicines and the onset of diabetic retinopathy
This study will test whether newer diabetes medicines (SGLT2 and DPP‑4 inhibitors) can delay diabetic retinopathy in people with type 2 diabetes who've had the disease for more than five years and have been on diabetes medications for 2–3 years.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.